PLUS THERAPEUTICS, INC.

Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.

PSTV | US

Overview

Corporate Details

ISIN(s):: US23283K2042 (+1 more)
LEI:
Country:: United States of America
Address:: 4200 MARATHON BLVD., 78756 AUSTIN
Website:: http://www.plustherapeutics.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's proprietary platform is designed to deliver a single, high-dose of radiation directly to tumors while minimizing damage to healthy tissue. This is achieved by encapsulating Rhenium radioisotopes within novel delivery systems like nanoliposomes and biodegradable microspheres. Its lead drug candidate, REYOBIQ™ (rhenium Re186 obisbemeda), targets central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases. The company's pipeline also includes a next-generation therapy for solid organ cancers, such as liver cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
JCR Pharmaceuticals Co.,Ltd. Develops therapies for rare genetic diseases, CNS disorders, and regenerative medicine.	Japan	4552
JEIL PHARMACEUTICAL CO.,LTD Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.	South Korea	271980
JEIL PHARMA HOLDINGS INC. Develops and distributes APIs, generics, and modified drugs, specializing in injections.	South Korea	002620
JETEMA Co.,Ltd. Research-driven developer of aesthetic toxins, dermal fillers, and threads.	South Korea	216080
JIN YANG PHARMACEUTICAL. CO., LTD Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.	South Korea	007370
JOHNSON & JOHNSON Develops innovative medicines and medical technologies for complex diseases and personalized care.	United States of America	JNJ
Journey Medical Corp A pharmaceutical firm commercializing prescription drugs and generics for dermatology.	United States of America	DERM
JUPITER NEUROSCIENCES, INC. Pharma firm developing resveratrol treatments for neuroinflammation and rare diseases.	United States of America	JUNS
JW LIFESCIENCE CORPORATION A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.	South Korea	234080
JW SHINYAK CORPORATION Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.	South Korea	067290